Zai Lab (ZLAB) Return on Capital Employed (2021 - 2026)
Zai Lab (ZLAB) posted Return on Capital Employed of 32.72% for Q1 2026, down 6.9% sequentially from 30.61% in Q4 2025, and down 154.0% YoY from 60.6% in Q1 2025.
Zai Lab (ZLAB) Return on Capital Employed (2021 - 2026) Analysis & Trends
Zai Lab has reported Return on Capital Employed for 6 years, with the latest figure at 32.72% in Q1 2026.
- Quarterly Return on Capital Employed fell 154.0% year-over-year to 32.72% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 32.72% (down 154.0% YoY) and the FY2025 annual result came in at 30.07%, up 469.0% from the prior year.
- Return on Capital Employed slipped to 32.72% in Q1 2026 per ZLAB's latest filing, from 30.61% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 28.43% in Q3 2025 and troughed at 48.31% in Q3 2024.
- A 5-year average of 37.69% and a median of 36.81% in 2023 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed slumped 1254 bps in 2024, then soared 1988 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 36.12% in 2022, then fell by 21 bps to 43.8% in 2023, then rose by 18 bps to 35.89% in 2024, then climbed by 15 bps to 30.61% in 2025, then decreased by 7 bps to 32.72% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 32.72%, 30.61%, and 28.43% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Zai Lab | 2.91 Bn | 2.20 Bn | 58.15 Mn | -40.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -40.22% |
| Mar 31, 2026 | -32.72% |
| Dec 31, 2025 | -30.61% |
| Sep 30, 2025 | -28.43% |
| Jun 30, 2025 | -29.50% |
| Mar 31, 2025 | -31.19% |
| Dec 31, 2024 | -35.89% |
| Sep 30, 2024 | -48.31% |
| Jun 30, 2024 | -48.08% |
| Mar 31, 2024 | -44.79% |
| Dec 31, 2023 | -43.80% |
| Sep 30, 2023 | -35.77% |
| Jun 30, 2023 | -38.30% |
| Mar 31, 2023 | -36.81% |
| Dec 31, 2022 | -36.12% |
| Sep 30, 2022 | -43.74% |
| Jun 30, 2022 | -37.25% |
| Mar 31, 2022 | -39.47% |
| Dec 31, 2021 | -47.43% |
| Sep 30, 2021 | -33.90% |